読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$3.76
−$0.06 · -1.57%
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
前日終値
$3.76
−$0.06 · -1.57%
時間外
$3.77
+$0.01 · +0.27%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
日中レンジ
現在 $3.76
52週レンジ
現在 $3.76
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
85
大幅な割安
センチメント
57
まちまち
リスク
46
やや高いリスク
モメンタム
74
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
日中レンジ
現在 $3.76
52週レンジ
現在 $3.76
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.96億 USD | 3.51億 USD | 4.43億 USD | 4.11億 USD | 4.14億 USD |
| 売上原価 | — | 755.2万 USD | 614.8万 USD | 141.8万 USD | 7040.5万 USD |
| 粗利益 | 2.96億 USD | 3.44億 USD | 4.37億 USD | 4.09億 USD | 3.43億 USD |
| 研究開発 | 9513.6万 USD | 1.11億 USD | 1.16億 USD | 4426.5万 USD | 7040.5万 USD |
| 販売・一般管理 | 8225.6万 USD | — | — | 1.16億 USD | — |
| 営業費用 | 1.77億 USD | 2.51億 USD | 13.82億 USD | 1.59億 USD | 1.11億 USD |
| 受取利息 | 407.6万 USD | 446.8万 USD | 1897.1万 USD | 950.1万 USD | 72.6万 USD |
| 支払利息 | 3274.6万 USD | 3303.4万 USD | 2162.9万 USD | 759.8万 USD | 3115万 USD |
| 減価償却費と償却費 | 188.1万 USD | 201.1万 USD | 157.5万 USD | 141.8万 USD | 150万 USD |
| 営業利益 | 1.19億 USD | 9312.4万 USD | −9.45億 USD | 2.5億 USD | 2.32億 USD |
| 純利益 | 2401.7万 USD | 88万 USD | −10.02億 USD | 1.75億 USD | 5.28億 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$6.68
上昇余地（77.66%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年4月2日 | 597:500 | — | — |
発効済み 2019年4月2日
597:500
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2032.13万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM1638.39万0.02%787.4億 USD0.19%$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1248.97万0.13%98.74億 USD0.35%$151.4-1.54%
Vanguard Extended Market ETFVXF720.06万0.01%954億 USD0.05%$233.52-0.63%
iShares Russell 2000 Growth ETFIWO550.6万0.04%139.17億 USD0.24%$353.71-0.86%
Pacer US Small Cap Cash Cows ETFCALF502.74万0.14%35.87億 USD0.59%$54.76+0.18%
iShares Biotechnology ETFIBB478.52万0.04%108.2億 USD0.44%$204.26-1.08%
Dimensional - US Small Cap ETFDFAS446.76万0.01%338.69億 USD0.31%$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOPacer US Small Cap Cash Cows ETFCALFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
